All In Biotech

Drug Trial Radar · NCT04869358

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

Tracking the Immune Response to SARS-CoV-2 modRNA Vaccines in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS)

Last checked: Nov 20, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

34

Actual

Start

May 27, 2021

Primary completion

May 10, 2022

Study completion Jun 13, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation of ofatumumab treatment or at least 4 weeks after commencing ofatumumab treatment.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • OfatumumabDrug

    Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Having Established SARS-CoV-2-specific T Cells After Receiving a modRNA VaccineTime frame: 1 month after second dose of vaccine or booster vaccine

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bielefeld, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Erbach im Odenwald, Germany

  • Novartis Investigative Site

    Siegen, Germany

  • Novartis Investigative Site

    Unterhaching, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.